A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

1. Viéitez, J.M.
2. Valladares, M.
3. Peláez, I.
4. De Sande González, L.
5. García-Foncillas, J.
6. García-López, J.L.
7. García-Girón, C.
8. Reboredo, M.
9. Bovio, H.
10. Lacave, A.J.